Friday, May 29, 2009

Why Obama Should Lower Capital Gains Taxes for VC's

First of all, I voted for Obama, but I believe he is completely off target on capital gains tax, because of the negative effect it has on innovation, job creation, and the proper multiplier effect.

Capital gains taxes should be lowered across the board to encourage investment in equities, since these companies can create more jobs in a healthy stock environment and have more money to invest in new developments. In turn, the resultant bump this will give to equities will generate more revenues (wealth creation) for individuals and corporations, and, in turn, for the government from increased capital gains and corporate tax receipts. Why doesn't Obama get this?

Certainly, government coffers are lower now, because of the stock market crash. Stimulating investments in stocks through a capital gains reduction will create massive revenues for the government, reduce the need for other tax increases, build consumer confidence, and get people spending again. That's how jobs are created. The primary reason the Clinton administration had a budget surplus was due to a robust stock market during most of his tenure. Reducing capital gains will help insure a return to this form of prosperity.

More importantly, there should be a moratorium or elimination of capital gains taxes on income derived from investing in venture capital. Why? Venture capital is the riskiest capital there is. It should be rewarded for this risk, yet it is treated the same as public equity. Traditionally, it invests in the most innovative, risky technologies. Today, it is so hard for VC's to raise money, they are investing more and more in later stage companies and staying away from true innovation. Without innovation, this country becomes an also ran, which is basically what eight years of Bush has made us.

VC's deserve a bigger cut in capital gains tax, because it takes years to obtain a return on investment. Furthermore, we need VC to get back to fueling innovation, something on which the US economy is dependent for its future well being. China and India are graduating a multiple of the engineers in every discipline than we are in the US. Their VC industry is not as developed as in the US, but ironically, more and more US VC dollars are being invested in these countries, because of the low cost of labor. Furthermore, many of these nations have no capital gains tax. This means innovation is beginning to become far less an advantage of the US, and it is essentially getting exported along with our manufacturing jobs.

We are losing and will continue to lose manufacturing jobs and venture capital investment dollars to nations with a lower cost of labor. In just the year 2007, Ohio lost 25% of its manufacturing jobs, mostly due to lower cost overseas producers. Read that last sentence again. It's astounding. Putting up trade barriers is just plain idiotic. It will only cause our consumers to pay more for everything. 

What will replace these lost jobs? We have an 8.6% unemployment rate in the US, and it's rising. Obama's plan of spending money will temporarily stimulate the economy and create some jobs, but most of these stimulus dollars have a low multiplier effect. Innovation has a far high multiplier effect. Government spending has the lowest multiplier effect of any form of spending in our economy, and of government spending, military spending has the lowest multiplier effect of all. Obama's plan is not a long term solution to our country's need. On capital gains, Obama completely misses the point. When he first started campaigning, he wanted to increase capital gains from 18% to 30%. Advisors (probably Warren Buffett) talked him down to 20%, but this is still in the wrong direction. It should be noted that Buffett makes few, if any, investments in innovation.

This country desperately needs to retrain its work force for jobs of the future. These jobs will come primarily from IT, biotech and other life sciences, and new forms of energy. 

Take healthcare, for example. Baby boomers are entering their disease prone years, so they will need much more healthcare in the years to come. Healthcare, as a percentage of GDP, is expected to rise from 16-17% today to nearly 20% of GDP by 2017. That's one out of every five dollars, and the rise as a percentage of GDP for healthcare is unlikely to stop there. People are living longer, and they will need more care for decades to come.

That will create a lot of jobs, but we do not have enough doctors and nurses today. We need to concentrate on why this is and fix it. Besides, doctors and nurses are jobs that cannot be exported due to cheaper labor, unless a patient is willing to travel abroad for less expensive operations. This traveling abroad for operations, by the way, is happening more and more as our cost of health care rises. Unfortunately, all too often, people are getting what they pay for when they do this. I know one lady who went to India for a colon cancer operation, and they did not even save a piece of her cancer to make a personalized vaccine to help her boost the antibodies in her system against the cancer, something that more and more major cancer centers are doing in the US. 

One big source of our health care cost rise is our archaic legal system, which encourages malpractice suits, even when there has been no malpractice - more on that in another blog. As a result, fewer people want to become doctors, or they are leaving the profession altogether, because they cannot afford the malpractice insurance. Even if they can afford the insurance, this cost must be passed onto the patient, further driving up healthcare costs. 

But the biggest reason for the increase in our cost of healthcare is we are not investing enough in new technologies and therapeutics that can reduce the cost of our healthcare. These technologies exist, yet there is little money to fund them. Great companies with life saving, life extending and cost saving technologies are going bankrupt everyday, because there is not enough venture capital to advance these companies. This means there is not enough money to advance the creation of the types of jobs that can backfill the loss of traditional manufacturing jobs to overseas companies. Also, new medical technologies would create a whole new class of manufacturing jobs. This requires us to educate and retrain our workforce for this new economy. Fortunately, Obama gets this part of the equation.

Unfortunately, today venture capital companies are having great difficulty raising funds, since many of the endowments, fund of funds, and state pension funds that feed their coffers have reduced their allotments to VC, due to heavy losses sustained in the equities portion of their portfolios. As a result, this nation is investing a much smaller amount into innovation than it was a just a couple years ago. 

Yes, it is promising that the Obama administration has boosted NIH spending by $10B, but NIH grants are usually quite small and are not nearly enough to make up for the great shortfall in venture capital. In 2008, there was roughly $29B spent by the NIH on 46,000 grants, which means the average grant was $630,000. This spurns a lot of fundamental research, which is great, but it is not enough money to bring these great discoveries to market.  Bringing new cancer therapies and vaccines to market can cost tens and hundreds of millions of dollars, and much of this money must come from venture capital, since big pharma is mostly interested in products showing success in Phase III trials. NIH dollars are not nearly large enough to fund the vast majority of clinical trials.

This shortage of capital creates another problem. It forces VC's to invest in what can get to the market the fastest, not necessarily the best solutions. For instance, billions have been invested in small molecule drugs, one because they can get to the market more quickly, and two because big pharma likes to sell pills that you need to take every day for a long time, regardless of the side effects. Biologics, on the other hand, can be more expensive in the short run to develop, but they are often a more effective therapeutic, with fewer side effects, if any, and they are less expensive overall as a therapeutic. However, for big pharma biologics are a nightmare, since they cannot realize the same margins on products that work better, faster and cheaper. This will change, because either they will get funded in this country or abroad. Better always wins out in the end. Companies like Roche get this, which is why they bought Genentech.

The future cannot be avoided forever. The evidence of this is that for the last few years, the FDA has started to approve more biologics for the market than drugs for the first time in history. However, with the present shortage of VC dollars, this trend to better healthcare is threatened. 

Because the primary sources of venture capital have dried up, reducing or eliminating capital gains tax for VC's will help this country promote the level of innovation necessary to make it more competitive. We are a debtor nation that imports far more than we export. Without proper incentives to invest in innovation, that will only continue. 

______________________



Thursday, May 28, 2009

GBP Health / Biotech News 05-28-2009

GBP Health / Biotech News 05-28-2009:

Since August, 2005, this news digest has been a complimentary service of GBP Capital, a private equity firm investing in early to mid-stage life science companies. See www.gbpcap.com. The digest is published two to four days a week. If you have colleagues who would be interested in receiving this digest by email, they can be added to the list at: http://www.gbpcap.com/ <http://www.gbpcap.com/> .  Also, the complete history of the entire content of all news articles in our digests since August, 2005 is searchable with Google's enterprise search engine at the same site.   

Source - EurekAlert – Biology

Public Release: 28-May-2009
American Journal of Physiology: Heart and Circulatory Physiology
Adult bone marrow stem cells injected into skeletal muscle can repair heart tissue <http://www.buffalo.edu/news/10132>
University at Buffalo researchers have demonstrated for the first time that injecting adult bone marrow stem cells into skeletal muscle can repair cardiac tissue, reversing heart failure.
National Institutes of Health, New York State Stem Cell Science
Contact: Lois Baker
ljbaker@buffalo.edu
<mailto:ljbaker@buffalo.edu>
716-645-5000 x1417
University at Buffalo
<http://www.buffalo.edu>

Public Release: 28-May-2009
FASEB Journal
Scientists develop a new HIV microbicide -- and a way to mass produce it in plants <http://www.eurekalert.org/pub_releases/2009-05/foas-sda052809.php>
In what could be a major pharmaceutical breakthrough, research published online in the FASEB Journal describes how scientists from St George's, University of London have devised a one-two punch to stop HIV. First the report describes a new protein that can kill the virus when used as a microbicide. Then the report shows how it might be possible to manufacture this protein in quantities large enough to make it affordable for people in developing countries.
Contact: Cody Mooneyhan
cmooneyhan@faseb.org <mailto:cmooneyhan@faseb.org>
301-634-7104
Federation of American Societies for Experimental Biology
<http://www.faseb.org>

Public Release: 28-May-2009
Cell
Study may aid efforts to prevent uncontrolled cell division in cancer <http://www.eurekalert.org/pub_releases/2009-05/uoc--sma052709.php>
Researchers from the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine have uncovered a remarkable property of the contractile ring, a structure required for cell division. Understanding how the contractile ring works to divide the cell may facilitate development of therapies to prevent uncontrolled cell division in cancer.
Ludwig Institute for Cancer Research, Pew Scholars Program in the Biomedical Sciences, Fundação para a Ciência e Tecnologia, European Social Fund
Contact: Steve Benowitz
sbenowitz@ucsd.edu <mailto:sbenowitz@ucsd.edu>
619-543-6163
University of California - San Diego
<http://www.ucsd.edu>

Public Release: 28-May-2009
Cell
The vulnerable cancer cell <http://www.hhmi.org/news/synlethal20090529.html>
Howard Hughes Medical Institute researchers have identified many potential new drug targets for cancers long deemed "untouchable" due to the type of genetic mutation they contain. These studies are beginning to reveal new ways of attacking cancer by targeting a largely hidden network of normal genes that cancer cells rely on for survival.
Contact: Jim Keeley
keeleyj@hhmi.org <mailto:keeleyj@hhmi.org>
301-215-8858
Howard Hughes Medical Institute
<http://www.hhmi.org>

Public Release: 28-May-2009
Hitting cancer where it hurts <http://www.eurekalert.org/pub_releases/2009-05/cp-hcw052209.php>
Two studies in the May 29 issue of Cell, a Cell Press publication, have taken advantage of new technological advances to search for and find previously unknown weaknesses in a hard to treat form of cancer. The discoveries lend new hope in the fight again tumors that are today considered "undruggable."
Contact: Cathleen Genova
cgenova@cell.com <mailto:cgenova@cell.com>
617-397-2802
Cell Press <http://www.cellpress.com>

Public Release: 27-May-2009
Thyroid
First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal <http://www.eurekalert.org/pub_releases/2009-05/mali-fcg052709.php>
New guidelines designed to standardize and optimize the diagnosis, treatment, and monitoring of patients with medullary thyroid carcinoma , an uncommon and challenging form of thyroid cancer, have been developed by the American Thyroid Association and published online ahead of print in Thyroid, a peer-reviewed journal published by Mary Ann Liebert Inc. The guidelines are available free online.
Contact: Vicki Cohn
vcohn@liebertpub.com <mailto:vcohn@liebertpub.com>
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News <http://www.liebertpub.com>
 
Public Release: 26-May-2009
PLoS Biology
In a rare disorder, a familiar protein disrupts gene function <http://www.eurekalert.org/pub_releases/2009-05/plos-iar052109.php>
In this week's PLoS Biology, an international team of scientists studying a rare genetic disease has discovered that a bundle of proteins already known to be important for keeping chromosomes together also plays an important role in regulating gene expression in humans. In addition to shedding light on the biological roles of these proteins, the research may lead to the development of better diagnostic tools for Cornelia de Lange syndrome, a multisystem developmental disease.
Contact: Sally Hubbard
press@plos.org <mailto:press@plos.org>
Public Library of Science <http://www.plos.org>

Public Release: 26-May-2009
PLoS Biology
What is the function of lymph nodes? <http://www.eurekalert.org/pub_releases/2009-05/plos-wit052109.php>
A new paper, published in this week's issue of PLoS Biology, suggests that lymph nodes are not essential in the mouse in marshaling T-cells (a main immune foot soldier) to respond to a breach of the skin barrier. This result is both surprising in itself, and suggests a novel function for the liver as an alternate site for T-cell activation.
Contact: Sally Hubbard
press@plos.org <mailto:press@plos.org>
Public Library of Science <http://www.plos.org>

Public Release: 26-May-2009
PLoS Biology
Viruses are sneakier than we thought <http://www.eurekalert.org/pub_releases/2009-05/plos-vas052109.php>
Of central importance for viruses is the ability to commandeer cellular gene expression machinery. Several human herpes viruses put the breaks on normal cellular gene expression to divert the associated enzymes and resources towards their own viral genes. Kaposi's sarcoma-associated herpes virus, which causes several AIDS-associated cancers, has now been shown to do this in an unexpected way, using a process that is normally protective, called polyadenylation.
Contact: Sally Hubbard
press@plos.org <mailto:press@plos.org>
Public Library of Science <http://www.plos.org>

Public Release: 26-May-2009
PLoS Biology
Meet the complete mouse -- whole mouse genome sequence published <http://www.eurekalert.org/pub_releases/2009-05/plos-mtc052109.php>
A new paper, published in this week's issue of PLoS Biology, explores exactly what distinguishes our genome from that of the lab mouse. In the first comprehensive comparison between the genes of mice and humans, scientists from institutions across America, Sweden and the UK reveal that there are more genetic differences between the two species than had been previously thought.
Contact: Sally Hubbard
press@plos.org <mailto:press@plos.org>
Public Library of Science <http://www.plos.org>

Public Release: 26-May-2009
Disease Models & Mechanisms
Zebrafish provide a model for cancerous melanoma in humans <http://www.eurekalert.org/pub_releases/2009-05/tcob-zpa051909.php>
In a new study published in Disease Models & Mechanisms, scientists use the zebrafish to gain insight into the influence of known cancer genes on the development and progression of melanoma, an aggressive form of human skin cancer with limited treatment options.
Contact: Sarah Sharpe
sarah.sharpe@biologists.com <mailto:sarah.sharpe@biologists.com>
The Company of Biologists <http://www.biologists.com>

Public Release: 25-May-2009
Proceedings of the National Academy of Sciences
Nervous system may be culprit in deadly muscle disease <http://www.eurekalert.org/pub_releases/2009-05/uof-nsm052109.php>
Long considered a "muscle" disorder, Pompe disease may have a previously unknown neural component. In mouse models of the disease, University of Florida researchers have discovered that signals from the spinal cord are too weak to reach the diaphragm -- the muscle that controls breathing. The finding suggests that therapies to treat the disease will need to take the central nervous system into account in order to be fully effective.
National Institutes of Health
Contact: John Pastor
jdpastor@ufl.edu <mailto:jdpastor@ufl.edu>
352-273-5815
University of Florida <http://www.ufl.edu>

Public Release: 25-May-2009
European Human Genetics Conference 2009
Identification of genetic variants affecting age at menopause could help improve fertility treatment <http://www.eurekalert.org/pub_releases/2009-05/esoh-iog052109.php>
For the first time, scientists have been able to identify genetic factors that influence the age at which natural menopause occurs in women. Ms. Lisette Stolk, a researcher from Erasmus MC, Rotterdam, the Netherlands, told the annual conference of the European Society of Human Genetics today that a greater understanding of the factors influencing age at menopause might eventually help to improve the clinical treatment of infertile women.
Contact: Mary Rice
mary@mrcommunication.org <mailto:mary@mrcommunication.org>
European Society of Human Genetics <http://www.eshg.org>

Public Release: 25-May-2009
European Human Genetics Conference 2009
Scientists find shared genetic link between the dental disease periodontitis and heart attack <http://www.eurekalert.org/pub_releases/2009-05/esoh-sfs052109.php>
The relationship between the dental disease periodontitis and coronary heart disease has been known for several years. Although a genetic link seemed likely, until now its existence was uncertain. Now, for the first time, scientists have discovered a genetic relationship between the two conditions, a researcher told the annual conference of the European Society of Human Genetics today.
Contact: Mary Rice
mary@mrcommunication.org <mailto:mary@mrcommunication.org>
European Society of Human Genetics <http://www.eshg.org>

Public Release: 25-May-2009
Journal of Cell Biology
Heart saves muscle <http://www.eurekalert.org/pub_releases/2009-05/rup-hsm051809.php>
A heart muscle protein can replace its missing skeletal muscle counterpart to give mice with myopathy a long and active life, show Nowak et al.
Contact: Rita Sullivan
news@rupress.org <mailto:news@rupress.org>
212-327-8603
Rockefeller University Press <http://www.rockefeller.edu/RUPress/>

Source - Science Daily:

Please note: Due to the format restrictions of Science Daily articles, you must click on the URL (web address) below the article summary, rather than the article title.
 
New Therapy Enlists Immune System To Boost Cure Rate In Childhood Cancer <http://www.sciencedaily.com/releases/2009/05/090527181540.htm>
May 28, 2009
— Scientist have announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the ...
http://www.sciencedaily.com/releases/2009/05/090527181540.htm

New Cellular Targets For HIV Drug Development <http://www.sciencedaily.com/releases/2009/05/090527181544.htm>
May 28, 2009
— Focusing HIV drug development on immune cells called macrophages could help combat the disease, according to new ...
http://www.sciencedaily.com/releases/2009/05/090527181544.htm

The Vulnerable Cancer Cell: New Studies Reveal Broad, Hidden Network That Lets Tumors Thrive <http://www.sciencedaily.com/releases/2009/05/090528120647.htm>
May 28, 2009
— Researchers have identified many potential new drug targets for cancers long deemed "untouchable" due to the type of genetic mutation they contain. These studies are beginning to reveal new ways of ...
http://www.sciencedaily.com/releases/2009/05/090528120647.htm

Genetic Testing For Breast Or Ovarian Cancer Risk May Be Greatly Underutilized
May 27, 2009
— Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with ...
http://www.sciencedaily.com/releases/2009/05/090521131315.htm

Less-toxic Drug Prolongs Survival In Metastatic Breast Cancer <http://www.sciencedaily.com/releases/2009/05/090526162846.htm>
May 27, 2009
— A less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug. Abraxane ...
http://www.sciencedaily.com/releases/2009/05/090526162846.htm

Green Tea Extract Shows Promise In Leukemia Trials <http://www.sciencedaily.com/releases/2009/05/090526163010.htm>
May 27, 2009
— Researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate, an active ingredient in green ...
http://www.sciencedaily.com/releases/2009/05/090526163010.htm

Can We Afford The Cancer Care Of The Future? <http://www.sciencedaily.com/releases/2009/05/090526140751.htm>
May 27, 2009
— When a cancer patient and his or her doctor discuss the value of a treatment option, the conversation usually centers on a consideration of the treatment's medical benefits versus its possible side ...
http://www.sciencedaily.com/releases/2009/05/090526140751.htm

Newly Discovered Mechanism Promotes Blood Clot Formation <http://www.sciencedaily.com/releases/2009/05/090526094300.htm>
May 26, 2009
— Researchers in Australia have discovered an entirely new mechanism that promotes blood clot formation -- a major breakthrough that will impact on treatment and prevention of heart disease and ...
http://www.sciencedaily.com/releases/2009/05/090526094300.htm

Protein Identified As Critical To Insulating The Body's Wiring Could Also Become Treatment Target <http://www.sciencedaily.com/releases/2009/05/090519134826.htm>
May 26, 2009
— A new protein identified as critical to insulating the wiring that connects the brain and body could one day be a treatment target for divergent diseases, from rare ones that lower the pain threshold ...
http://www.sciencedaily.com/releases/2009/05/090519134826.htm

How Viral Infection Can Protect From Type 1 Diabetes <http://www.sciencedaily.com/releases/2009/05/090526171807.htm>
May 26, 2009
— Type 1 diabetes is caused by immune system–mediated destruction of insulin-producing beta-cells in the pancreas. It is known that infection with a virus can induce an immune response that ...
http://www.sciencedaily.com/releases/2009/05/090526171807.htm

New Broad-spectrum Vaccine To Prevent Cervical Cancer Induces Strong Responses In Animals <http://www.sciencedaily.com/releases/2009/05/090526162842.htm>
May 26, 2009
— Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus type 16 four months after ...
http://www.sciencedaily.com/releases/2009/05/090526162842.htm

Activated Stem Cells In Damaged Lungs Could Be First Step Toward Cancer <http://www.sciencedaily.com/releases/2009/05/090526140856.htm>
May 26, 2009
— Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a new ...
http://www.sciencedaily.com/releases/2009/05/090526140856.htm

Stem Cells Transplanted From Marrow Into Heart May Improve Heart's Performance <http://www.sciencedaily.com/releases/2009/05/090526094616.htm>
May 26, 2009
— Scientists are carrying out clinical tests with patients who have suffered from a severe heart attack. With the implantation of the patient’s stem cells, the heart regenerates thus improving ...
http://www.sciencedaily.com/releases/2009/05/090526094616.htm

Virus Tamed To Destroy Cancer Cells But Leave Healthy Cells Unharmed <http://www.sciencedaily.com/releases/2009/05/090522081217.htm>
May 25, 2009
— Scientists have tamed a virus so that it attacks and destroys cancer cells but does not harm healthy cells. They have determined how to produce replication-competent viruses with key toxicities ...
http://www.sciencedaily.com/releases/2009/05/090522081217.htm

Efficacy Of CT Scans For Chest Pain Diagnosis Validated <http://www.sciencedaily.com/releases/2009/05/090515104219.htm>
May 23, 2009
— The first long-term study following a large number of chest pain patients who are screened with coronary computerized tomographic angiography confirms that the test is a safe, effective way to rule ...
http://www.sciencedaily.com/releases/2009/05/090515104219.htm

Intelligent Life Sciences Search Engine: Grid Browser Understands Technical Terms And Context <http://www.sciencedaily.com/releases/2009/05/090521084719.htm>
May 23, 2009
— A web browser that can understand technical terms in life sciences and automatically find additional resources and services has been developed. It could lead to a new generation of intelligent search ...
http://www.sciencedaily.com/releases/2009/05/090521084719.htm

Source - Health Day:

Health Highlights: May 27, 2009 <http://www.healthday.com/Article.asp?AID=627471>
  • Test for Early Alzheimer's Moving Forward: Report
  • Minnesota Boy to Undergo Chemotherapy
  • Court Rules 'Light' Cigarettes Duped Smokers
U.S. Cancer Death Rates Continue to Fall
Report finds 19.2% drop among men, 11.4% among women in past 15 years.

Drug May Extend Life When Breast Cancer Spreads <http://www.healthday.com/Article.asp?AID=627382>
Study funded by pharmaceutical company finds benefits in Abraxane

Too Much Cola Can Cause Muscle Problems <http://www.healthday.com/Article.asp?AID=627269>
Drop in potassium levels may lead to mild weakness or temporary paralysis, study finds

Hardened Arteries Threaten Obese, Diabetic Youth <http://www.healthday.com/Article.asp?AID=627295>
Ultrasound shows damage tied to rising odds for stroke, heart attack, researchers say

Clinical Trials Update: May 26, 2009 <http://www.healthday.com/Article.asp?AID=627430>
  • Constipation
  • Depression (Adult and Geriatric)
  • Conjunctivitis, Bacterial
  • Schizophrenia
  • Healthy Volunteers
  • Alzheimer's Disease 

Source - Yahoo Biotech News:
 
New Stem Cell Web Site to Focus on Traumatic Brain Injury, Spinal Cord Injury and Diabetes <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/prnews/090528/la23532.html?.v=1>  - PR Newswire - Thu 10:30 am ET
Entest BioMedical, Inc., a newly formed wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group, Inc. announced today the launch of its Web site to focus on new stem cell research, including a proposed research to develop a new therapeutic solution for traumatic brain injury using autologous adipose-derived stem cells representing a potential cure.

New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/prnews/090527/la22782.html?.v=1>  - PR Newswire - Wed 9:00 am ET
Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population

International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/bw/090527/20090527005366.html?.v=1>  - Business Wire - Wed 8:30 am ET
OCEANSIDE, Calif.----International Stem Cell Corporation , the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, has received positive early results from animal trials designed to improve photorefractive keratectomy , a form of corrective laser eye surgery that offers an improved alternative to LASIK.

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338 <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/prnews/090527/ph22695.html?.v=1>  - PR Newswire - Wed 8:00 am ET
Clinical study planned for relapsed / refractory acute myelogenous leukemia-

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/prnews/090527/sf22808.html?.v=1>  - PR Newswire - Wed 7:00 am ET
Longer term follow-up indicates modest efficacy in primary and related endpoints --

Independent Data Monitoring Board Recommends Continuation to Completion of Genta's Phase 3 Trial of Genasense
� in Advanced Melanoma <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/bw/090519/20090519005206.html?.v=1>  - Business Wire - Tue May 19
BERKELEY HEIGHTS, N.J.----Genta Incorporated today announced that the independent Data Monitoring Board for AGENDA, a randomized Phase 3 trial of Genasense
in patients with advanced melanoma, has informed the Company that the study has passed its final futility analysis for progression-free survival .

Source - Google Health News:


Sanofi Pasteur Receives Order from US Government to Produce New ... <http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/05-25-2009/0005031981&EDATE=>
PR Newswire (press release) - New York,NY,USA
Previously, we developed and licensed the first pre-pandemic vaccine for H5N1 and we look forward to further demonstrating our experience and expertise in ...
 
Russian researchers begin to make H1N1 vaccine <http://www.zeenews.com/news534338.html>
Zee News - Noida,Uttar Pradesh,India
Moscow, May 25: Russian researchers have begun preparations to create a vaccine against the H1N1 swine flu after a strain of the virus was received from a ...
 
Australia defends flu steps as global cases rise <http://www.google.com/hostednews/afp/article/ALeqM5g0yjeucxbIFK4f1zsVemLgdXvQjg>
AFP
SYDNEY (AFP) — Australia on Saturday defended its escalation of swine flu protection measures as global health chiefs said a vaccine could be ready as early ...
 
 
For Flu Vaccine, US Sets Aside $1 Billion <http://online.wsj.com/article/SB124303594956748749.html>
Wall Street Journal - USA
... with which it already has contracts to produce a pandemic vaccine -- contracts that were focused on the possibility of a pandemic of H5N1 avian flu. ...

Team hopes to start testing H1N1 vaccine within weeks <http://www.purdueexponent.com/index.php/module/Section/section_id/3?module=article&story_id=16681>
The Exponent - West Lafayette,IN,USA
... testing a vaccine on mice in the next couple of weeks. “We are trying to use a similar approach as we did with the H5N1 bird flu virus,” Mittal said. ...

H1N1 synthetic flu may be test run for H5N1 avian flu <http://onlinejournal.com/artman/publish/article_4730.shtml>
Online Journal - Silver Springs,FL,USA
However, there are misgivings in the international research community about administering an AH1N1 vaccine. The fear is that once a vaccination against ...

Source - Medical News Today:

What Is A Heart Attack? What Causes A Heart Attack? <http://www.medicalnewstoday.com/articles/151444.php>
If the heart muscle does not have enough blood (and consequently oxygen) it dies and a heart attack occurs. Another name for a heart attack is myocardial infarction, cardiac infarction and coronary thrombosis. According to Medilexicon's medical dictionary <
http://www.medilexicon.com/medicaldictionary.php> , a heart attack is "infarction of a segment of heart muscle, usually due to occlusion of a coronary artery". (Infarction = the process whereby an area of dead tissue is caused by a loss of blood supply).   A heart attack usually happens when a blood clot develops in one of the blood vessels that lead to the heart muscle (coronary arteries). The clot, if it is big enough, can stop the supply of blood to the heart. Blood supply to the heart can also be undermined if the artery suddenly narrows, as in a spasm.
http://www.medicalnewstoday.com/articles/151444.php

Call To Tackle The Causes Of Ageing Rather Than Treating The Effects <
http://www.medicalnewstoday.com/articles/151516.php>
Tackling the very causes of ageing, rather than treating the symptoms in a piecemeal way offers the best prospects for dealing with the diseases and effects of ageing according to a public lecture being given at the Royal Society tonight.   New research that offers up hope to improve health during ageing in humans, and to tackle a broad range of ageing-related diseases, will be presented tonight by Director of the UCL Institute of Healthy Ageing Professor Linda Partridge. She believes these scientific advances are inspiring a new wave in ageing research.
http://www.medicalnewstoday.com/articles/151516.php

MIT Researchers Develop Implantable Device To Monitor Cancer, Tissue Scaffold To Regrow Cartilage And Bone <
http://www.medicalnewstoday.com/articles/151494.php>
Surgical removal of a tissue sample is now the standard for diagnosing cancer. And while biopsies are accurate, they only offer a snapshot of the tumor at a single moment in time.   Monitoring a tumor for weeks or months after the biopsy, tracking its growth, and studying how it responds to treatment would be much more valuable, says Michael Cima, professor of materials science and engineering at the Massachusetts Institute of Technology, who has developed the first implantable device to do just that. "What this does is basically take the lab and put it in the patient," says Cima. The devices, which are designed to be implanted at the time of biopsy, could be tailored to monitor chemotherapy agents, allowing doctors to determine whether cancer drugs are reaching the tumors. They also can be designed to measure pH or oxygen levels, which would reveal a tumor's metabolism and response to therapy. The cylindrical, 5-millimeter implant contains magnetic nanoparticles coated with antibodies specific to the target molecules. Target molecules enter the implant through a semipermeable membrane, bind to the particles, and cause them to clump together -- a process that can be detected by MRI. The device is composed of polyethylene, which is commonly used in orthopedic implants. The semipermeable membrane, which allows target molecules to enter but traps the magnetic nanoparticles inside, is fabricated of polycarbonate, a compound used in many plastics. Cima's team studied the device by transplanting human tumors into mice, then using the implants to track levels of human chorionic gonadotropin, a hormone produced by human tumor cells, for more than a month. They reported their findings in ronics. Biosensors & Bioelectronics. <
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TFC-4W32KKR-5&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=6735e6b02700aedac852d1d3bb>  Cima believes an implant to test for pH levels could be commercially available in a few years, followed by devices to test for complex chemicals such as hormones and drugs.
http://www.medicalnewstoday.com/articles/151494.php

Healing Wounds With Lasers <
http://www.medicalnewstoday.com/articles/151449.php>
Researchers from around the world will present the latest breakthroughs in electro-optics, lasers and the application of light waves at the 2009 Conference on Lasers and Electro-Optics/International Quantum Electronics Conference (CLEO/IQEC) May 31 to June 5 at the Baltimore Convention Center in Baltimore.
http://www.medicalnewstoday.com/articles/151449.php

New Strategies For Cell Therapy To Regenerate Damaged Heart <
http://www.medicalnewstoday.com/articles/151346.php>
Research undertaken at the Center for Applied Medical Research (CIMA) and the University Hospital of Navarra has shown that, in animal models, stem cells <
http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>  derived from bone marrow and adipose tissue enhance heart function after a cardiac attack. In concrete, bone marrow cells act on the damaged tissue, while fatty cells have the ability to transform themselves into both blood vessels and cardiac cells. The results obtained with rats are maintained over a long time period, explained biochemist Mr Manuel Mazo, principal researcher.  When a person suffers a heart attack, the artery feeding the heart is obstructed The affected tissue dies and the scar tissue left des not contract. It is a serious problem as cardiac muscle does not regenerate, with grave consequences for the functional capacity of the heart, a situation which can trigger heart failure, explained the scientist.
http://www.medicalnewstoday.com/articles/151346.php

Alarming Rise In Deadly Skin Cancer Cases, UK <
http://www.medicalnewstoday.com/articles/151317.php>
There has been an alarming rise in new cases of the deadliest form of skin cancer in the UK, with binge tanning cited as a main reason, said a leading cancer charity.
The number of UK people diagnosed with malignant melanoma, the potentially fatal type of skin cancer. has gone over the 10,000 barrier to reach an all time high of 10,400 according to figures released earlier today by Cancer Research UK.
http://www.medicalnewstoday.com/articles/151317.php <http://www.medicalnewstoday.com/articles/151317.php>

 
 
 
Source - MIT's Technology Review:

 
First Acoustic Superlens
http://www.technologyreview.com/biomedicine/22710/

What's the Point in Patenting Genes? <
http://www.technologyreview.com/biomedicine/22704/?nlid=2055>
http://www.technologyreview.com/biomedicine/22704/?nlid=2055

Better Brain-Wave Analysis <
http://www.technologyreview.com/biomedicine/22696/?nlid=2052>
http://www.technologyreview.com/biomedicine/22696/?nlid=2052

Reducing Toxicity of Chemotherapy For Brain Cancer

This article was co-written with Dr. Boro Dropulic, President and CSO of Lentigen Corporation (see: http://www.lentigen.com)

Glioblastoma Mulitiforme (GBM), a form of brain cancer, is a highly debilitating, most often fatal disease, with many patients dying within a year after diagnosis.  The current mode for treatment of GBM is a combination of radiation and chemotherapy which extends life, but it is not a cure. The chemotherapy uses a drug called Temozolomide (TMZ), or Tedomar, which can effectively kill GBM cancer cells.  However, the drug cannot be used at desired higher dose levels because of its toxicity to the blood-forming  stem cells which help create a major part of our immune system. As a result, often before the TMZ can kill off the GBM, the patient's immune system is so highly compromised that they die of the cancer or other diseases. 

Evidence that higher doses of TMZ could dramatically help treat GBM comes from recent evidence that cancer stem cells can be killed more effectively by higher or denser dosing with TMZ. The question is how to protect the bone marrow stem cells of the immune system, so that the TMZ has time to kill the cancer? In other words, how to we get to using higher doses of TMZ without destroying the blood forming (hematopoietic) marrow stem cells (HSC)? 

Lentigen is close to Phase I clinical testing of LG631, a Lentiviral vector that delivers a gene payload (MGMT - methylguanine-DNA-methyltransferase) into HSCs to make them resistant to the toxic effects of TMZ.  The goal is to develop this therapy into an effective treatment for GBM by protecting HSCs with LG631 so that physicians can treat patients with higher and denser doses of TMZ, so as to more effectively treat the disease.  The excitement for this clinical trial is supported by preclinical work performed in multiple top research institutions in the US, including validation of the protection of HSCs in the presence of high TMZ levels in multiple animal models, including mice, dogs and non-human primates.  Lentigen hopes to start this clinical trial later this year.

TMZ is in the family of chemotherapies called alkylating agents, many of which have similar off-target effects of killing off major parts of the patients' immune systems (HSC's), and if successful with GBM, Lentigen anticipates this opening up opportunities to use the same therapeutic approach with these other alkylating agents.

 

Sunday, May 24, 2009

Reducing Lamin A Protein. A Cure For Aging?

Everyone gets emails touting anti-aging solutions from skin creams to vitamin supplements, and it is difficult to know for decades whether any of these work. They may have temporary effects, but they are all designed for you to keep taking them - good for business.

Certainly reducing free radicals by boosting antioxidants helps. Avoiding carcinogenic activities like too much exposure to the sun, smoking tobacco, avoiding contact with chemicals ending in "-ium" can help, but these do not get at why we really age.

There is an interesting blog on why we age at: http://hubpages.com/hub/Why-do-we-age. This blog lists a number of aging related causes, but leaves out perhaps the single biggest one, the buildup of a protein, called Lamin A. 

The surface of the cell nucleus of our cells is a porous structure called the lamina. Inside the lamina is our DNA, all mangled up like a bowl of spaghetti. The openings of the lamina meshwork allow proteins, mRNA and other molecules to pass in and out of the nucleus. Our lamina is made up of two proteins, Lamin A and Lamin C. 

As we age, Lamin A is continually produced by our bodies, and over time, it builds up on the lamina, causing it to shrivel like a raisin. In microcosm, it resembles a porous raisin, but in aggregation, it shows up as wrinkles in our skin and is a chief contributor as to why we shrink when we age.

There may be an even greater concern with this lamin A buildup. As the lamina shrinks, some scientists believe it may cause pressure on our double helical DNA, resulting in damage. When we have DNA damage, often a strand of DNA breaks and flaps around, until one of our 700 DNA damage repair proteins repairs the breakage. However, if it is, indeed, the case that shrinking lamina causes excess DNA damage, it may be too much for our DNA damage repair proteins to keep up with the repair, which could help lead to the many diseases of aging. 

In May, 2006, a published study showed that when the lamin A protein was inhibited in aged mice, not only did the shriveling of their lamina cease, but their lamina became plump again. OK, if this works in humans, and there are no off-target effects of reducing lamin A production, we have a valuable solution to wrinkling. However, more importantly, if it's true that shrinkage of the lamina contributes significantly to DNA damage, we may have reduced the incidence of age related diseases, since the shrinking lamina would no longer be putting pressure on our DNA.

For more info on this see: http://tinyurl.com/qldqth

How can this cure for aging be properly put to the test? One thought has been to establish a clinical trial for patients with the disease progeria, a childhood disorder that rapidly accelerates aging, where people with this disorder rarely live past their 20's, at which point they appear to be in their 80's or 90's. It's not clear this would work, since progeria is a different disorder of the lamina where cytosine is replaced by thymine in position 1824 of the LMNA gene. 

See: http://en.wikipedia.org/wiki/Progeria

However, perhaps there will be a gene therapy to fix this disorder in people with progeria. It is highly unlikely simply reducing the production of lamin A protein will alter the cytosine/thymine issue.

The difficulty with reducing or inhibiting (knocking down) the production of lamin A protein on normal healthy people is that the results would not be known for decades, unless it is tried on older people. Certainly, if it works on older people, wrinkles should reduce or disappear quickly. Also, if the theory is correct that shrinkage of the lamina results in more damage to the DNA, then this group of trials should show a reduction in the diseases associated with aging. It would be interesting to know if the effect on mice would be similar to those on humans.

For more info on Lamin A and the gene LMNA, see: http://ghr.nlm.nih.gov/gene=lmna


Saturday, May 23, 2009

Integrated Cancer Therapeutics

Getting from here to there:

Where is "here"? 

Today, the standard of regimen in most hospitals treating cancer patients with solid tumors is to surgically remove as much of the tumor as possible, and subsequently, treat the patients with one or more chemotherapies and/or radiation, perhaps coupled with a biologic, such as Avastin, which helps shrink the blood supply to the tumor. 

There's really not any one part of this treatment regimen that is all good, except that right now, sometimes it works to rid the patient of the cancer, and often it may prolong the life of the patient, sometimes by only a few months. The surgery is highly invasive, often removing healthy tissue along with the tumor(s). The chemo often has severe off-target effects that are highly debilitating - nausea, vomiting, destruction of healthy cells, loss of hair, and sometimes destruction of the immune system. The same pretty much goes for radiation, and Avastin, depending on the application, can have its own set of complications and off-target effects.

And then there is the long anxious wait to see if the cancer returns.

Where is "there"? 

An integration of new and traditional therapies is evolving. Multimillion dollar proton beam radiation machines enable highly targeted "boiling" of the tumor cells in prostate cancer, minimizing the collateral damage to nearby healthy cells without any surgery required. However, even in cases where this technology can be used, there is still the need to follow up with chemo or radiation to make sure that residual cancer cells are destroyed. 

There is a new form of radiation that targets only the cancer, by helping guide the radiation use MRI to minimize collateral damage to healthy tissue. See: <http://www.medicalnewstoday.com/articles/150774.php>.

Also, MRI focussed ultrasound has many of the same benefits.
See: http://www.tmcnet.com/usubmit/2009/05/24/4194253.htm

Potentially, more effective methods of boosting the immune system can bypass the need for chemo altogether, or it can be used as a supplement to chemo to "mop up" the residual cancer cells following traditional cancer therapies. Often patients are deemed cancer free, only to have their cancer return. Companies today, such as MabVax (see: www.mabvax.com) are working with vaccine technologies developed over the last two decades at Memorial Sloan Kettering Cancer Center in NY to boost the antibodies in the patient following traditional therapies in order to help prevent the cancer from recurring. MabVax's vaccines are still in clinical trials, but if progress continues, it could offer an inexpensive method of helping prevent the cancer from returning by boosting antibodies against the particular form of cancer.

The idea of cancer vaccines have been around for decades, and indeed, the vaccine for human papilloma virus (HPV) has been is the market in nearly 90 countries. However, for other cancers, producing effective prophylactic vaccines has been more difficult, as enough of the right antibodies have failed to be produced. For more information on MabVax, see:
www.mabvax.com

In the first edition of this blog, the T-cell expansion work of Dr. Carl June and his team at the University of Pennsylvania has demonstrated strong anecdotal immune response in fighting cancer, and where possible, they find improved results by making a personalized vaccine from the patient's own cancer. This approach is being replicated by numerous major cancer centers around the US. Right now, there is no web site for the company that has been established around Dr. June's T-cell expansion, as the company is still in stealth mode. However, Dr. June and his team already has clearance for 18 FDA clinical trials and has treated 400 cancer patients with variations of this approach. There is enough anecdotal evidence to show that this therapeutic holds great promise. See the first blog at this site for more detail.

Today, there is no therapeutic vaccine for cancer that will work alone. Where we may be headed with solid mass tumors is an integrated set of cancer therapies to:

1.  Use a proton beam or MRI guided radiation, or
2.  Surgically remove as much of the cancer as possible, and then
3.  Use cancer specific T-cell expansion to mop up the remaining cancer cell, along with a personalized vaccine made from the patient's own cancer, and then 
4.  Later take a vaccine to boost cancer specific antibodies to help prevent the cancer from returning. 
5.  If  the cancer does return, it should be detected early enough so that all that may be needed is another T-cell expansion. 

For hematological cancers (cancers of the blood) T-cell expansion and follow up vaccines show promising relief from chemo, bone marrow transplants (with their risk of graft versus host disease) and radiation.

Scientists are developing methods to detect cancer earlier.  With that, perhaps only T-cell expansion and vaccines will be necessary - a totally non-invasive and effective approach to cancer therapeutics. Should we get to this point, the harmful side effects of chemo and radiation may become a thing of the past. There may still be some cancers that prove more difficult for these new modes of therapeutics, such as glioblastoma (a cancer of the brain). The good news is there are developments in the works to tackle these difficult cancers using novel approaches. More on that in a future blog.

_______


Friday, May 22, 2009

GBP Health / Biotech News 05-22-2009


Since August, 2005, this news digest has been a complimentary service of GBP Capital, a private equity firm investing in early to mid-stage life science companies. See www.gbpcap.com. The digest is published two to four days a week. If you have colleagues who would be interested in receiving this digest by email, they can be added to the list at: http://www.gbpcap.com/ <http://www.gbpcap.com/> .  Also, the complete history of the entire content of all news articles in our digests since August, 2005 is searchable with Google's enterprise search engine at the same site.   

Source - EurekAlert – Biology

Public Release: 22-May-2009
Science in China Series C: Life Sciences
The challenges of avian influenza virus: Mechanism, epidemiology and control <http://www.eurekalert.org/pub_releases/2009-05/sicp-tco052209.php>
The latest special issue of Science in China Series C: Life Sciences focuses on the recent progress in the H5N1-related research field.
Chinese Natural Science Foundation, Chinese Basic Science Research Program, National Key Basic Research and Development Program of China
Contact: Li Jiyuan
ljy@scichina.org <mailto:ljy@scichina.org>
86-106-401-5399
Science in China Press <http://zh.scichina.com/english/>


Public Release: 21-May-2009
Cancer Epidemiology Biomarkers & Prevention
Protein predicts development of invasive breast cancer in women with DCIS, Penn study shows <http://www.eurekalert.org/pub_releases/2009-05/uops-ppd052109.php>
Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer, according to a new study from the University of Pennsylvania School of Medicine. The results, published in the May issue of the journal Cancer Epidemiology, Biomarkers and Prevention, may help clinicians distinguish between DCIS that requires minimal treatment and DCIS that should be treated more aggressively.
Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine <http://pennhealth.com/news>


 
Public Release: 21-May-2009
Cell Stem Cell
Gene therapy could expand stem cells' promise <http://news.med.cornell.edu/wcmc/wcmc_2009/05_21_09.shtml>
Once placed into a patient's body, stem cells intended to treat or cure a disease could end up wreaking havoc simply because they are no longer under the control of the clinician. But gene therapy has the potential to solve this problem, according to a perspective article from physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center published in a recent issue of the journal Cell Stem Cell.
Contact: John Rodgers
jdr2001@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College <http://www.med.cornell.edu>


 
Public Release: 21-May-2009
Journal of General Internal Medicine
Genetic testing for breast or ovarian cancer risk may be greatly underutilized <http://www.eurekalert.org/pub_releases/2009-05/mgh-gtf052109.php>
Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers.
Dana-Farber/Harvard Cancer Center
Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital <http://www.mgh.harvard.edu>


 
Public Release: 21-May-2009
Journal of Biological Chemistry
LSUHSC research describes function of key protein in cancer spread <http://www.eurekalert.org/pub_releases/2009-05/lsuh-lrd052109.php>
Research led by David Worthylake, Ph.D., Assistant Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, may help lay the groundwork for the development of a compound to prevent the spread of cancer.
Louisiana Board of Regents
Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center <http://www.lsumc.edu>


 
Public Release: 21-May-2009
Lancet
Diabetics' heart attack risk can be reduced, research finds <http://www.eurekalert.org/pub_releases/2009-05/uoc-dha052009.php>
People with diabetes who maintain intensive, low blood sugar levels are significantly less likely to suffer heart attacks and coronary heart disease, new research published today in the Lancet has shown.
British Heart Foundation
Contact: Genevieve Maul
genevieve.maul@admin.cam.ac.uk
44-122-333-2300
University of Cambridge <http://www.cam.ac.uk>


 
Public Release: 21-May-2009
PLoS Pathogens
MicroRNA regulation of tumor-killing viruses avoids unwanted viral pathology <http://www.eurekalert.org/pub_releases/2009-05/plos-mro051809.php>
Scientists have determined how to produce replication-competent viruses with key toxicities removed, providing a new platform for development of improved cancer treatments and better vaccines for a broad range of viral diseases.
Contact: Emma Gilgunn-Jones
emma.gilgunn-jones@cancer.org.uk
44-207-061-8311
Public Library of Science <http://www.plos.org>


 
Public Release: 21-May-2009
Cell
'Happy hour' gene discovery suggests cancer drugs might treat alcoholism <http://www.eurekalert.org/pub_releases/2009-05/cp-gd051409.php>
A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That's the conclusion of a discovery in flies of a gene, dubbed "happy hour," that has an important and previously unknown role in controlling the insects' response to alcohol.
Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press <http://www.cellpress.com>


 
Public Release: 21-May-2009
American Society for Microbiology 109th General Meeting
Preventing ear infections in the future: Delivering vaccine through the skin <http://www.eurekalert.org/pub_releases/2009-05/asfm-pei051409.php>
An experimental vaccine applied the surface of the skin appears to protect against certain types of ear infections. Scientists from the Research Institute at Nationwide Children's Hospital in Columbus, Ohio, report their findings today at the 109th General Meeting of the American Society for Microbiology in Philadelphia.
Contact: Jim Sliwa
202-942-9297
American Society for Microbiology <http://www.asm.org>


 
Public Release: 21-May-2009
PLoS Genetics
Key protein may explain the anti-aging and anti-cancer benefits of dietary restriction <http://www.eurekalert.org/pub_releases/2009-05/bifa-kpm051309.php>
A protein that plays a key role in tumor formation, oxygen metabolism and inflammation is involved in a pathway that extends lifespan by dietary restriction. The finding, by scientists at the Buck Institute, provides a new understanding of how dietary restriction contributes to longevity and cancer prevention and gives scientists new targets for developing and testing drugs that could extend the healthy years of life.
Ellison Medical Foundation, Larry L. Hillblom Foundation, American Federation for Aging Research, Bill and Rita Haynes Foundation, NIH/National Institute on Aging
Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2080
Buck Institute for Age Research <http://www.buckinstitute.org>


 
Public Release: 20-May-2009
American Journal of Physical Medicine and Rehabilitation
MIT robotic therapy holds promise for cerebral palsy <http://www.eurekalert.org/pub_releases/2009-05/miot-mrt052009.php>
Over the past few years, MIT engineers have successfully tested robotic devices to help stroke patients learn to control their arms and legs. Now, they're building on that work to help children with cerebral palsy.
Cerebral Palsy International Research Foundation, Niarchos Foundation, US Department of Veterans Affairs, New York State NYSCORE, National Center for Medical Rehabilitation Research
Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology <http://web.mit.edu/newsoffice>


 
Public Release: 20-May-2009
Oligonucleotides
Strong immune response to new siRNA drugs in development may cause toxic side effects <http://www.eurekalert.org/pub_releases/2009-05/mali-sir052009.php>
Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects. Understanding how siRNA stimulates this undesirable immune activity, how to test for it, and how to design siRNA drugs to avoid it are critical topics explored in a timely review article published online ahead of print in Oligonucleotides.
Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News <http://www.liebertpub.com>


 
Public Release: 19-May-2009
NeuroImage
U of Minnesota researcher develops brain-scanning process that holds promise for epilepsy treatments <http://www.eurekalert.org/pub_releases/2009-05/uom-uom051909.php>
University of Minnesota McKnight professor and director of Center for Neuroengineering Bin He has developed a new technique that has led to preliminary successes in noninvasive imaging of seizure foci. He's technique promises to play an important role in the treatment of epileptic seizures.
National Institutes of Health, National Science Foundation
Contact: Patty Mattern
mattern@umn.edu
612-624-2801
University of Minnesota <http://www.umn.edu>


 
Public Release: 19-May-2009
European Journal of Organic Chemistry
A new way of treating the flu <http://www.eurekalert.org/pub_releases/2009-05/rpi-anw051909.php>
Promising new research announced by Rensselaer Polytechnic Institute could provide an entirely new tool to combat the flu. The discovery is a one-two punch against the illness that targets the illness on two fronts, going one critical step further than any currently available flu drug.
National Institutes of Health
Contact: Gabrielle DeMarco
demarg@rpi.edu
518-276-6542
Rensselaer Polytechnic Institute <http://www.rpi.edu/News>


 
Source - Science Daily:

Please note: Due to the format restrictions of Science Daily articles, you must click on the URL (web address) below the article summary, rather than the article title.
 
Why Do People With Down Syndrome Have Less Cancer? Research In Mice And Human Stem Cells Suggests New Therapeutic Targets <http://www.sciencedaily.com/releases/2009/05/090520140359.htm>
Most cancers are rare in people with Down syndrome. The late cancer researcher Judah Folkman, M.D., proposed that the extra copy of chromosome 21 may contain a ...
http://www.sciencedaily.com/releases/2009/05/090520140359.htm

Gene Therapy Could Expand Stem Cells' Promise <http://www.sciencedaily.com/releases/2009/05/090521131317.htm>
May 22, 2009
— Once placed into a patient's body, stem cells intended to treat or cure a disease could end up wreaking havoc simply because they are no longer under the control of the clinician. But gene therapy ...
http://www.sciencedaily.com/releases/2009/05/090521131317.htm <http://www.sciencedaily.com/releases/2009/05/090521131317.htm>
 
Adult Stem Cells From Bone Marrow Made To Kill Metastatic Lung Cancer Cells In Mice <http://www.sciencedaily.com/releases/2009/05/090519172051.htm>
May 22, 2009
— Researchers have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors. The genetically engineered stem cells ...
http://www.sciencedaily.com/releases/2009/05/090519172051.htm <http://www.sciencedaily.com/releases/2009/05/090519172051.htm>
 
New Vaccine Strategy Might Offer Protection Against Pandemic Influenza Strains <http://www.sciencedaily.com/releases/2009/05/090518120954.htm>
May 22, 2009
— A novel vaccine strategy using virus-like particles could provide stronger and longer-lasting influenza vaccines with a significantly shorter development and production time than current ones, ...
http://www.sciencedaily.com/releases/2009/05/090518120954.htm <http://www.sciencedaily.com/releases/2009/05/090518120954.htm>

Triple Drug Combination Is Promising Option To Treat Metastatic HER2+ Breast Cancer <http://www.sciencedaily.com/releases/2009/05/090515093234.htm>
May 22, 2009
— Combining two chemotherapy drugs with trastuzumab to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment ...
http://www.sciencedaily.com/releases/2009/05/090515093234.htm <http://www.sciencedaily.com/releases/2009/05/090515093234.htm>
 
Early Identification Of Dementia Increasingly Difficult <http://www.sciencedaily.com/releases/2009/05/090517152559.htm>
May 22, 2009
— If grandma seems to forget things, will she end up demented? These days, memory loss is one of the very few symptoms that may signal which 70-year-olds risk developing ...
http://www.sciencedaily.com/releases/2009/05/090517152559.htm <http://www.sciencedaily.com/releases/2009/05/090517152559.htm>
 
Bone Marrow Cell Therapy May Be Beneficial For Patients With Ischemic Heart Disease <http://www.sciencedaily.com/releases/2009/05/090519172103.htm>
May 22, 2009
— The injection of bone marrow cells into the heart of patients with chronic myocardial ischemia (reduced blood flow to some areas of the heart) was associated with modest improvements in blood flow ...
http://www.sciencedaily.com/releases/2009/05/090519172103.htm <http://www.sciencedaily.com/releases/2009/05/090519172103.htm>
 
New Strategies For Cell Therapy To Regenerate Damaged Heart <http://www.sciencedaily.com/releases/2009/05/090520055517.htm>
May 21, 2009
— In animal models, stem cells derived from bone marrow and adipose tissue enhance heart function after a cardiac ...
http://www.sciencedaily.com/releases/2009/05/090520055517.htm <http://www.sciencedaily.com/releases/2009/05/090520055517.htm>
 
Cancer Stem Cells May Be Related To Prognosis In Primary Breast Cancer <http://www.sciencedaily.com/releases/2009/05/090514221931.htm>
May 21, 2009
— Breast cancer patients who received chemotherapy prior to surgery had heightened levels of cancer-initiating stem cells in their bone marrow, and the level of such cells correlated to a tumor's lymph ...
http://www.sciencedaily.com/releases/2009/05/090514221931.htm <http://www.sciencedaily.com/releases/2009/05/090514221931.htm>
 
AIDS Patients With Serious Complications Benefit From Early Retroviral Use, Study Shows <http://www.sciencedaily.com/releases/2009/05/090516174342.htm>
May 21, 2009
— HIV-positive patients who don't seek medical attention until they have a serious AIDS-related condition can reduce their risk of death or other complications by half if they get antiretroviral ...
http://www.sciencedaily.com/releases/2009/05/090516174342.htm <http://www.sciencedaily.com/releases/2009/05/090516174342.htm>
 
Automated Analysis Of MR Images May Identify Early Alzheimer’s Disease <http://www.sciencedaily.com/releases/2009/05/090521171444.htm>
May 21, 2009
— Analyzing MRI studies of the brain may allow diagnosis of Alzheimer's disease and of mild cognitive impairment, a lesser form of dementia that precedes the development of Alzheimer's by several ...
http://www.sciencedaily.com/releases/2009/05/090521171444.htm <http://www.sciencedaily.com/releases/2009/05/090521171444.htm>
 
Genetic Testing For Breast Or Ovarian Cancer Risk May Be Greatly Underutilized <http://www.sciencedaily.com/releases/2009/05/090521131315.htm>
May 21, 2009
— Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with ...
http://www.sciencedaily.com/releases/2009/05/090521131315.htm <http://www.sciencedaily.com/releases/2009/05/090521131315.htm>
 
Function Of Key Protein In Cancer Spread Described <http://www.sciencedaily.com/releases/2009/05/090521112829.htm>
May 21, 2009
— New research may help lay the groundwork for the development of a compound to prevent the spread of ...
http://www.sciencedaily.com/releases/2009/05/090521112829.htm <http://www.sciencedaily.com/releases/2009/05/090521112829.htm>
 
Old Diabetes Drug Teaches Experts New Tricks <http://www.sciencedaily.com/releases/2009/05/090514153136.htm>
May 20, 2009
— New research reveals that the drug most commonly used in type 2 diabetics who don't need insulin works on a much more basic level than once thought, treating persistently elevated blood sugar -- the ...
http://www.sciencedaily.com/releases/2009/05/090514153136.htm

Epigenetics: 100 Reasons To Change The Way We Think About Genetics <http://www.sciencedaily.com/releases/2009/05/090518111723.htm>
May 20, 2009
— Increasingly, biologists are finding that non-genetic variation acquired during the life of an organism can sometimes be passed on to offspring -- a phenomenon known as epigenetic inheritance. A new ...
http://www.sciencedaily.com/releases/2009/05/090518111723.htm

Surprise 'Spark' For Pre-cancerous Colon Polyps <http://www.sciencedaily.com/releases/2009/05/090514125154.htm>
May 19, 2009
— Researchers have studied the events leading to colon cancer and found that an unexpected protein serves as the "spark" that triggers formation of colon polyps, the precursors to cancerous ...
http://www.sciencedaily.com/releases/2009/05/090514125154.htm

 
 
 
Source - Health Day:

Health Highlights: May 21, 2009 <http://www.healthday.com/Article.asp?AID=627320>
  • No Decline in Pregnant Women's Alcohol Use: CDC
  • Japanese Women Have Longest Life Expectancy: WHO
  • Chronic Ills Common Among Adults With Public Insurance: Study
  • Many U.S. College Students Feel Stressed: Survey
  • Costly Hospital Care Doesn't Guarantee Better-Quality Care: Study
  • Young Children's Deaths Decline 27%: WHO
Advanced Prostate Cancer Deadlier in Younger Men
Patients under 44 were three times more likely to die, study finds.

Strict Blood Sugar Control Lowers Heart Risks in Diabetics
It prevents many complications of chronic disease, experts say.

Drug May Lessen Amputation Risk for Diabetics <http://www.healthday.com/Article.asp?AID=627317>
Researchers suggest that findings could alter treatment methods

A New Way to Get Chemo to Pancreatic Tumors <http://www.healthday.com/Article.asp?AID=627316>
Technique that doubles life span in mice may hold hope for people
Clinical Trials Update: May 21, 2009 <http://www.healthday.com/Article.asp?AID=627333>
  • Heartburn
  • Urticaria
  • Epilepsy
  • Migraine Headaches
  • Depression in Adults
  • Diabetic Peripheral Neuropathy

 
 
Source - Yahoo Biotech News:
 
 
Aastrom suspends trial following death of patient <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/ap/090522/us_aastrom_trial_suspended.html?.v=1>  - AP - Fri 7:58 am ET
Stem cell drug developer Aastrom Biosciences Inc. said Friday it suspended a clinical trial after received a report that a patient died some time after treatment.
 
Stem Cell Stocks Mixed on Heavy Volume Action <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/indie/090521/1952_id.html?.v=1>  - Indie Research - Thu 12:09 pm ET
Some stem cell stocks were up big on Thursday despite the market sell off.

Genzyme Submits All Information Requested by FDA for Lumizyme <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/bw/090521/20090521005700.html?.v=1>  - Business Wire - Thu 11:57 am ET
CAMBRIDGE, Mass.----Genzyme Corporation announced today that it has submitted the final documentation to address all items in the FDA's complete response letter for Lumizyme™ , produced at the 2,000 L bioreactor

HGSI asks for FDA approval of anthrax drug ABthrax <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/ap/090521/us_human_genome_sciences_anthrax.html?.v=1>  - AP - Thu 8:00 am ET
Human Genome Sciences Inc. said Thursday it asked the Food and Drug Administration to approve ABthrax, a drug it is developing to treat inhaled anthrax.

 
 
 
Source - Google Health News:


 
UN, WHO heads meet vaccine manufacturers <http://www.alertnet.org/thenews/newsdesk/WHOm/9f5fefcf28911b7fbbc66a6e278b184d.htm>
Reuters AlertNet - London,England,UK
Influenza A(H1N1) has a very different clinical picture, which is so far mostly mild and self-limiting, unlike H5N1, which had a 50% to 60% mortality rate. ...
 
 
Nearly five billion doses of swine flu vaccine possible: WHO <http://www.google.com/hostednews/afp/article/ALeqM5hwEIni0qoBrPF13qfXTloU_cuenA>
AFP
Indonesia, one of the countries hit by H5N1 bird flu, raised concerns two years ago about access to subsequent commercially developed vaccines for people in ...
 
 
WHO, GSK Provide Update on Pandemic Flu Production <http://pharmtech.findpharma.com/pharmtech/Manufacturing/WHO-GSK-Provide-Update-on-Pandemic-Flu-Production/ArticleStandard/Article/detail/599059?contextCategoryId=35097>
Pharmaceutical Technology Magazine - Iselin,NJ,USA
GSK also said it will convert its intended donation to WHO of 50 million doses of H5N1 prepandemic vaccine to the new candidate A (H1N1) adjuvanted ...
 
 
Vical Advances H1N1 Pandemic Influenza (Swine Flu) Vaccine <http://www.tradingmarkets.com/.site/news/Stock%20News/2339254/>
Trading Markets (press release) - Los Angeles,CA,USA
... whether the company's DNA vaccine candidate will be effective in protecting humans against H5N1, H1N1, or any other strains of influenza; ...
 
 
Officials Fear New H1N1 Could Mix With Drug-Resistant Strains <http://www.redorbit.com/news/health/1692174/officials_fear_new_h1n1_could_mix_with_drugresistant_strains/>
RedOrbit - Dallas,TX,USA
... it had not changed its position on vaccine access for poor countries since the issue initially came to the fore in connection with the H5N1 bird flu. ...
 
 
Gene Therapy Could Expand Stem Cells' Promise <http://www.healthnewsdigest.com/news/Research_270/Gene_Therapy_Could_Expand_Stem_Cells_Promise.shtml>
HealthNewsDigest.com - New York,NY,USA
But gene therapy has the potential to solve this problem, according to a perspective article from physician-scientists at NewYork-Presbyterian ...
 
 
Solid Lipid Nanoparticles Could Be Used In Gene Therapy <http://www.sciencedaily.com/releases/2009/05/090518103225.htm>
Science Daily (press release) - USA
ScienceDaily (May 18, 2009) — Gene therapy offers hope in treating diseases such as cystic fibrosis and disorders of the retina, as well as with more common ...

 
 
 
Source - Medical News Today:
 
Seasonal Flu Vaccine Unlikely To Protect Against New H1N1 Says CDC <http://www.medicalnewstoday.com/articles/151042.php>
According to the US Centers for Disease Control and Prevention (CDC), vaccination with seasonal flu vaccines made for the 2005 to 2009 seasons is unlikely to protect people against infection by the new A (H1N1) swine flu virus.  Scientists from the federal agency used banked blood samples taken before and after vaccination every year since 2005 and exposed them to the new swine flu virus. They reported the results of their investigations in the 19 May issue of their Morbidity and Mortality Weekly Report (MMWR).
http://www.medicalnewstoday.com/articles/151042.php

Genentech And Biogen Idec Submit Applications To The FDA For Rituxan For Most Common Type Of Adult Leukemia <
http://www.medicalnewstoday.com/articles/151096.php>
Genentech, Inc. and Biogen Idec (Nasdaq:BIIB) announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan <
http://www.medilexicon.com/drugs/rituxan.php> ® (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL). The companies will request a priority review, and if granted, anticipate the FDA will make a decision within six months.   CLL is the most common type of adult leukemia, accounting for one-third of all leukemias in the U.S. It is a slow-growing disease that occurs when too many abnormal white blood cells develop in the blood and bone marrow. The abnormal cells outnumber the normal white blood cells, making it difficult for the body to fight infection.
http://www.medicalnewstoday.com/articles/151096.php

The Difficulties Of Early Identification Of Dementia <http://www.medicalnewstoday.com/articles/150955.php>
If grandma seems to forget things, will she end up demented? These days, memory loss is one of the very few symptoms that may signal which 70-year-olds risk developing dementia. This is shown in a doctoral thesis at the Sahlgrenska Academy at the University of Gothenburg, Sweden.   Several of the tests previously used to predict which elderly individuals risk developing dementia do not seem to work any longer. The thesis shows that memory loss is the only factor that can still be used to indicate who is at risk, although not among the very old.
http://www.medicalnewstoday.com/articles/150955.php

Team Tracks Nanotube Cancer Killers In Live Tissue <http://www.medicalnewstoday.com/articles/150872.php>
Nanotechnology scientists at two Arkansas research institutions have developed a method of detecting, tracking, and killing cancer cells in real time with carbon nanotubes.  The discovery opens the prospect of a new, major front in the fight to eradicate cancer with promise for a new generation of cancer treatment beyond surgery, radiation, and chemotherapy.
http://www.medicalnewstoday.com/articles/150872.php

Revealing A Surprising Link Between Diabetes And Alzheimer's Disease <http://www.medicalnewstoday.com/articles/150847.php>
Blindness, heart disease, nerve damage, and kidney failure are not the only complications facing the nation's estimated 24 million people with diabetes <
http://www.medicalnewstoday.com/info/diabetes/whatisdiabetes.php> . Although not widely known, those with the disease face up to double the risk of developing Alzheimer's disease (AD) than non-diabetics, according to an article scheduled for the May 18 issue of Chemical & Engineering News, ACS' weekly newsmagazine.   C&EN senior editor Sophie Rovner explains in the article that people with diabetes tend to have a higher risk of getting AD, and possibly get it at an earlier age, than the general population. Five million people in the United States have Alzheimer's, a brain disorder that causes severe memory loss. Diabetes results from the body's inability to produce or use insulin. Newer research now suggests that insulin is critical for healthy nerve cells in the brain. As the hormone declines in the brains of people with Alzheimer's, so does their memory.
http://www.medicalnewstoday.com/articles/150847.php

Targeted Cancer Treatment Following Breakthrough In Radiotherapy <http://www.medicalnewstoday.com/articles/150774.php>
Current radiation therapy treatment damages a patient's healthy tissue as well as eradicating the tumour it is intended to destroy, making the treatment especially invasive and often causing nasty side effects.   A new development in radiotherapy will enable a far more precise and accurate treatment for cancerous tumours by using real-time images to guide the radiation beam.
http://www.medicalnewstoday.com/articles/150774.php

New Study May Help Understand How Alzheimer's Robs Sufferers Of Episodic Memory <http://www.medicalnewstoday.com/articles/150639.php>
Memory loss is love's great thief. Those who suffer aren't just the ones who can't remember - family, friends and loved ones agonize over how to react when the disorder begins its often inexorable progress.   Now, just-published research from scientists at the University of Georgia is offering new insights into how one kind of memory works. The study, published this week in the online edition of The Proceedings of the National Academy of Sciences, shows that laboratory rats have "episodic-like memory" and could open novel ways to study life-robbing loss of memory in humans.
http://www.medicalnewstoday.com/articles/150639.php

Individuals Who Have Low Levels Of 'Celebrex Gene' Are Resistant To Celebrex Treatment For Colon Tumor Prevention <http://www.medicalnewstoday.com/articles/150659.php>
A new study finds that individuals who have low expression of the "Celebrex gene," 15-PGDH, are actually resistant to Celebrex treatment when used to prevent colon cancer. The study, published in this week's issue of the Proceedings of the National Academy of Sciences (PNAS), is by Sanford Markowitz, M.D., Ph.D., the Markowitz-Ingalls Professor of Cancer Genetics at the Case Western Reserve University School of Medicine and an oncologist at the Ireland Cancer Center of University Hospitals Case Medical Center and his colleagues.  "These findings have two important practical implications," said Markowitz, who is also an investigator in the Howard Hughes Medical Institute. "First, they suggest that measurement of 15-PGDH may identify which individuals are most likely to benefit from treatment with Celecoxib as a colon tumor preventative. Second, they suggest that identifying drugs that could increase 15-PGDH expression in the colon could be a potent new strategy for preventing development of tumors in the colon."
http://www.medicalnewstoday.com/articles/150659.php

 
 
 
Source - MIT's Technology Review:

 
How Down Syndrome Stops Cancer <
http://www.technologyreview.com/biomedicine/22681/?nlid=2046>
http://www.technologyreview.com/biomedicine/22681/?nlid=2046

A Drug-Dispensing Lens <
http://www.technologyreview.com/biomedicine/22680/?nlid=2046>
http://www.technologyreview.com/biomedicine/22680/?nlid=2046

Sending Genes into the Brain <http://www.technologyreview.com/biomedicine/22675/?nlid=2042>
http://www.technologyreview.com/biomedicine/22675/?nlid=2042

Healing the Heart with Bone-Marrow Cells <
http://www.technologyreview.com/biomedicine/22676/?nlid=2042>
http://www.technologyreview.com/biomedicine/22676/?nlid=2042